Rapid Dose Therapeutics Profit Margin

The latest profit margin for RDTCF is -123.09% as of May 2026. That compares with -197.23% in the prior-year period — up 37.6% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Rapid Dose Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDTCF's profit margin moved from -197.23% to -123.09% — a 37.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rapid Dose Therapeutics's valuation or profitability profile.

Against Healthcare companies, RDTCF currently prints -123.09% for profit margin, while the sector average sits near 21.34%. That is roughly 676.9% below the sector mean. Large gaps often invite a closer look at Rapid Dose Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Rapid Dose Therapeutics converts resources into returns. At -123.09%, RDTCF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -197.23% in the prior-year period — up 37.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RDTCF's profit margin (-123.09%), review year-over-year change from -197.23%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.